Microarray Technology and Its Applications for Detecting Plasma microRNA Biomarkers in Digestive Tract Cancers.

Many cancers are known to be regulated by microRNAs (miRNAs), and the relationships between tissue miRNA expression levels and the amounts of miRNA circulating in the plasma (or plasma miRNA) have been examined in many types of cancers, including digestive tract cancers. The role of plasma miRNAs has yet to be elucidated in detail; therefore a comprehensive analysis of plasma miRNAs using microarrays should assist in establishing the utility of liquid biopsy or companion diagnosis. We here described the 3D-Gene(®) miRNA microarray (TORAY) currently used in our laboratory and introduced a trial application in digestive tract cancer diagnosis.

[1]  Jackeline Agorreta,et al.  microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells , 2009, Clinical Cancer Research.

[2]  D. Ichikawa,et al.  Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer , 2011, British Journal of Cancer.

[3]  J. Janssen,et al.  Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. , 2011, Pharmacogenomics.

[4]  M. L. Hastings,et al.  Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.

[5]  D. Ichikawa,et al.  Circulating microRNA in digestive tract cancers. , 2012, Gastroenterology.

[6]  D. Ichikawa,et al.  Circulating microRNAs in plasma of patients with gastric cancers , 2010, British Journal of Cancer.

[7]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[8]  Yuval Kluger,et al.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. , 2012, Journal of the National Cancer Institute.

[9]  A. Bardelli,et al.  Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. , 2014, Cancer treatment reviews.

[10]  Y. Matsuki,et al.  Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.

[11]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[12]  T Kawaguchi,et al.  Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma , 2012, British Journal of Cancer.

[13]  Nathalie Zahra,et al.  Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids , 2013, PloS one.

[14]  D. Ichikawa,et al.  Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma , 2011, British Journal of Cancer.

[15]  Jingde Zhu,et al.  DNA Methylation-regulated miR-193a-3p Dictates Resistance of Hepatocellular Carcinoma to 5-Fluorouracil via Repression of SRSF2 Expression* , 2011, The Journal of Biological Chemistry.

[16]  H. Hashimoto,et al.  Identification of altered MicroRNA expression patterns in synovial sarcoma , 2011, Genes, chromosomes & cancer.

[17]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[18]  G. Tsujimoto,et al.  Ultrasensitive DNA chip: gene expression profile analysis without RNA amplification. , 2006, Journal of Biochemistry (Tokyo).

[19]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.